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Abstract
BACKGROUND: Bladder cancer is notable for a striking heterogeneity of disease-specific risks.
Among the approximately 75% of incident cases found to be superficial to the muscularis propria
at the time of presentation (non-muscle-invasive bladder cancer), the risk of progression to the
lethal phenotype of muscle-invasive disease is strongly associated with stage and grade of disease.
Given the suggestion of an increasing percentage of low-risk cases in hospital-based registry data
in recent years, the authors hypothesized that population-based data may reveal changes in the
stage distribution of early-stage cases.
METHODS: Surveillance, Epidemiology, and End Results (SEER) data were used to examine
trends for the stage-specific incidence of bladder cancer between 1988 and 2006, adjusted for age,
race, and sex, using Joinpoint and nonparametric tests.
RESULTS: The adjusted incidence rate of papillary noninvasive (Ta) predominantly low grade
(77%) disease was found to increase from 5.52 to 9.09 per 100,000 population (P <.0001), with an
average annual percentage change of +3.3. Over the same period, concomitant, albeit smaller,
decreases were observed for flat in situ (Tis) and lamina propria-invasive (T1) disease (2.57 to
1.19 and 6.65 to 4.61 per 100,000 population [both P <.0001]; average annual percent change of
−5.0 and −1.6, respectively). The trend was most dramatic among patients in the oldest age strata,
suggesting a previously unappreciated cohort phenomenon.
CONCLUSIONS: The findings of the current study should motivate further epidemiological
investigations of differential associations of genetic and environmental factors with different
bladder cancer phenotypes as well as further scrutiny of clinical practice guideline
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recommendations for the growing subgroup of predominantly older patients with lower-risk
disease.
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INTRODUCTION
With a median age at diagnosis of 74 years, the burden of bladder cancer in the United
States is increasing, from approximately 50,000 new cases diagnosed per year between 1990
and 2000 to > 70,000 cases diagnosed since 2010.1 Many patients live with bladder cancer
as a chronic disease, and a recent estimate of prevalent cases was > 535,000.1 Given the
mandate for relatively intensive, often lifelong survivorship care2 and the comparatively
indolent natural history of the disease in many cases, bladder cancer has been associated
with the highest per-patient costs, from diagnosis to death, of all cancer sites.3 Incidence
rates are dramatically higher in patients aged > 65 years and peak at 179 cases per 100,000
population in patients aged 80 to 84 years, suggesting that the burden of this common cancer
will continue to substantially increase as the population ages.1
As with most solid cancers, the stage and grade of the tumor at the time of presentation
define the clinical significance of a bladder cancer diagnosis, and cases are first risk-
stratified by the presence or absence of invasion into the muscularis propria of the bladder
wall. Muscle-invasive cases (classified as ≥ T2) represent the lethal phenotype, with a 5-year
survival rate of approximately 50%, even in the face of aggressive management.4
Approximately 1 in 4 incident cases is muscle-invasive at the time of presentation. The
remainder of incident, non-muscle-invasive bladder cancer (NMIBC) is characterized by
uniformly high recurrence rates of NMIBC but starkly variable risks of progression to
muscle-invasive disease.5 A recent hospital-based registry study suggested the possibility of
an increased incidence of low-risk cases in recent years6; in this context, we hypothesized
that similar dynamic changes may be underway at the population level. Given the growing
burden of bladder cancer, the heterogeneous risk of different subphenotypes, and the
changing age structure of the population, we sought to characterize trends in stage-specific
incidence rates in the United States over the past 20 years.
MATERIALS AND METHODS
Study Population
We obtained cancer incidence data from the US National Cancer Institute (NCI)’s
Surveillance, Epidemiology, and End Results (SEER) Program using the November 2011
release.7 The case and SEER population data from all 18 registries were both downloaded
from the SEER Web site. To calculate incidence rates adjusted for age, race, and sex, we
also downloaded Census 2000 data as the “standard population” from the Web site.8 The
University of North Carolina Institutional Review Board exempted this study from review.
We subset the data to include cases of primary urinary bladder cancer that were diagnosed
between 1988 and 2006 using the SEER site recode code 29010, which maps to
International Statistical Classification of Diseases for Oncology (3rd edition) (ICD-O-3)
topography codes 67.0 to 67.9. The analysis was restricted to cases with transitional cell/
urothelial histology, the most common type of bladder cancer,4 using ICD-O-3 codes 8120,
8121, 8122, 8082, 8020, 8130, and 8131.9 The study period was chosen to begin in 1988 due
to the promulgation of a new 10-digit extent of disease (EOD) scheme in SEER that year,10
and terminated in 2006 due to the adoption of a new “multiple primaries” rule in 2007,
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which instructed registrars to code invasive tumors occurring ≥ 60 days after an index
noninvasive/in situ tumor as a new incident primary tumor.11 Due to changes in the
reporting of tumor stage over time, a crosswalk was developed using the codes from the
SEER EOD10,12and Collaborative Staging (CS)13 variables (Table 1). A total of 170,760
incident cases were identified. Among these, we excluded 72 cases for which the TNM T
classification was not of study interest (ie, T0 [8 cases] and stage IV [64 cases]), and
focused on the T classifications of Ta, Tis, T1, or ≥ T2. Cases that were staged as Tx (1017
cases) and unstaged cases (3960 cases) were combined and included as a separate category
for analytic purposes. Grading was defined as low (well-differentiated and moderately
differentiated), high (poorly differentiated and un-differentiated), and other/unknown.
Several sensitivity analyses were performed to gauge effects in changes of coding over time.
To examine arbitrary shifts in incidence rates over time, we performed a sensitivity analysis
reclas-sifying low-grade Tis cases to Ta because Tis cases are, by clinical definition, high
grade only.4 In addition, we performed a sensitivity analysis reclassifying Tx/unstaged cases
as Ta to confirm that the magnitude of changes in this group over the study period did not
account for the observed changes in the specified stages.
Statistical Analysis
From the SEER data, we summed the number of cases for each TNM T classification and
the underlying SEER population for each of the strata defined by age, race, and sex within
each year across the study period. Specifically, age was grouped into 7 categories (< 34
years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and ≥ 85 years); race
was coded as white, black, or other; and sex was coded as male or female. We also summed
the number of people from the standard population for each of the corresponding strata
described above to weight stratum-specific rates to calculate adjusted rates. The data set
contained covariates describing T classification, case count, SEER population count,
standard population count, year, and strata and were input into the Joinpoint Regression
Program (version 4.0.1; NCI, Bethesda, Md) to examine trends of stage-specific incidence
rates adjusted for age, race, and sex. Age strata-specific incidence rates adjusted for race and
sex were also analyzed. Joinpoint regression is a linear modeling approach that fits
incidence rate data (the dependent variable) for multiple years (the key independent
variable) and allows adjustment for factors such as age, race, and sex while standardizing
the incidence rates with the standard population. The program uses a sequence of
permutation tests to select a best-fit model with the smallest number of “joinpoints.”14 The
program uses the following steps to estimate model parameters and number of joinpoints: 1)
a weighted least-squares regression approach is used to find a best-fit model for each
possible number of joinpoints; and 2) permutation tests14 are used to determine the
maximum number of joinpoints by testing the hypothesis that adding more joinpoints does
not significantly improve model fit. To deal with small incidence rates, we selected a log-
linear model in the Joinpoint analysis.
Although Joinpoint regression allows for a trend analysis, it focuses on within-stratum
relative (percentage) changes, and does not have the flexibility to statistically test the
absolute difference between 2 incidence estimates within the same stage at 2 specified time
points or between 2 different stages at the same time point. To address this limitation, we
also computed standard errors15 (SEER*-Stat, NCI) for the adjusted rates for each T
classification over time. We then compared the differences between 2 rates using a
nonparametric method proposed by Carriere and Roos16 because this approach does not
require any assumptions that data originate from a known distribution. Specifically, this
method computes a Hotelling’s T-squared (T2) statistic, which follows a chi-square
distribution with a large sample. In a test comparing 2 rates, it is operationalized as a
squared t statistic for the 2-sample Student t test. All analyses except the Joinpoint
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regression models were performed using SAS statistical software (SAS Institute Inc, Cary,
NC).
RESULTS
The final cohort included 165,711 incident cases of staged primary urothelial carcinoma of
the bladder (hereafter referred to as bladder cancer) diagnosed between in 1988 and 2006 in
the 18 SEER registries. Among these, 79% of the cases were diagnosed at early stage (45%
with Ta disease, 24% with T1 disease, and 10% with Tis disease) whereas 21% were
diagnosed at late stage (≥T2) (Table 2).
The incidence rate adjusted for age, race, and sex (hereafter referred to as the adjusted
incidence rate) per 100,000 for bladder cancer of all stages was relatively stable (from 18.6
in 1988 to 18.8 in 2006) (Fig. 1). Similarly stable rates were observed when stratified by
early (< T2) versus late (≥ T2) stage (Fig. 1). However, the stage-stratified adjusted rates
within early-stage disease demonstrated a dramatic rise in the adjusted incidence rate of
noninvasive (Ta) disease, of which 77% were low grade (from 5.52 to 9.09) with
concomitant, albeit lesser in magnitude, decreases in the incidence rates for Tis (from 2.57
to 1.19) and T1 (6.65 to 4.61) disease (all P < .0001) (Table 3) (Fig. 2).14 Unstaged/stage Tx
cases represented a small minority (2.9% of the total cohort) and the adjusted incidence rates
in this group decreased over the study period (from 0.73 to 0.37; P < .0001) (Fig. 2).
The trends from Joinpoint regression analysis (Table 3) (Fig. 2) demonstrated that adjusted
incidence rates of Ta continuously increased between 1988 and 2006.14 The largest increase
occurred before 1991 (average annual percentage change [AAPC] of +11.2%), and slowed
down after 1991 (AAPC of +1.8%). In contrast, Tis decreased slowly before 2003 (AAPC of
−3.0%) and then accelerated from 2003 to 2006 (AAPC of −14.4%). The trend for T1
disease was less consistent, with an AAPC of −4.6% from 1988 to 1997, followed by an
AAPC of +1.6%. Finally, the trend for ≥ T2 disease increased at a constant and slow rate of
0.1% annually, and the rate for Tx/unstaged disease decreased with an AAPC of 5.1.
The stage-specific trends within age strata, adjusted for race and sex, revealed substantially
higher incidence rates for all stages of disease, as well as the greatest absolute and relative
increases of Ta incidence, among the older age strata (Fig. 3). The AAPC was +1.3 for those
aged 55 to 64 years and was over +3.0 for all other older age groups; this indicates that the
trend increase for Ta disease is more significant for older age groups than for the younger
age group. Joinpoint regression analysis for parallelism also suggested that the trends in Ta
incidence between all age groups were not parallel except among the 2 oldest age groups
(aged 75 years-84 years and aged ≥ 85 years; data not shown). Because the incidence rates
were very low for individuals aged < 55 years, data presented in the figure include only the
age strata for age ≥ 55 years.
In sensitivity analyses (Table 4) (Fig. 4A), when we reclassified Ta and Tis by moving the
low-grade Tis to Ta, the magnitude of the increase in the adjusted incidence of Ta over the
study period was attenuated but was still statistically significant (7.31 to 9.55 per 100,000; P
< .0001).14 With this reclassification, the incidence rate of Tis was more stable over time
(from 0.78 to 0.73 per 100,000). When we reclassified unstaged/Tx disease to Ta, the
magnitude of the increase in the adjusted incidence of Ta was attenuated but still statistically
significant (6.25 to 9.46 per 100,000; P < .0001) (Table 4) (Fig. 4 B).14
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We observed a shift in the stage-specific, age-, race-, and gender-adjusted incidence rates of
early stage bladder cancer in the United States over the past 20 years, with increasing
absolute and relative percentages of newly diagnosed cases of Ta disease (noninvasive
papillary), which is low grade in nearly 80% of cases. The proportional changes observed in
SEER data are consistent with results from a prior large hospital-based registry study
conducted between1993 and 2007.6 To the best of our knowledge, the current study is the
first to document this phenomenon in population-based data, affording the ability to measure
incidence rates, and demonstrates a statistically significant stage-specific increase in the rate
of noninvasive disease in analyses adjusted for age, race, and sex during this period (Fig. 2)
(Table 3). The most dramatic relative and absolute increases in Ta incidence occurred
among the oldest age strata, in which the overall burden of disease is also the highest (Fig.
3). The high, and rising, incidence rates in the elderly suggest that the burden of disease will
dramatically increase with the changing age structure of the population in coming decades.17
To the best of our knowledge, in contrast to other disease sites in which stage migration has
been documented, bladder cancer has rarely been detected incidentally at autopsy and there
has been no systematic screening program or fundamental change in the technology leading
to the diagnosis of bladder cancer (cystoscopy and transurethral resection of bladder tumor)
over the past 50 years.4 Therefore, these findings raise fundamental questions with regard to
bladder cancer epidemiology.
Because disease incidence is sensitive to changes in disease reporting, we examined changes
in grade and stage over the study period, particularly focusing on the classification of
carcinoma in situ, which is, by clinical definition, high grade only.4 When we reclassified
cases registered as low-grade Tis to Ta, the magnitude of the increase in Ta was slightly
attenuated, although still statistically significant (Fig. 4A) (Table 4). Further-more, although
the adjusted incidence rate of unstaged/Tx cases decreased over the study period, these cases
represented a very small percentage of the overall cohort, and a sensitivity analysis
reclassifying these cases as Ta did not change the overall findings (Fig. 4B), suggesting the
observed trends are not an artifact of more complete staging performed in later years of the
study. These findings underscore the proportionally large and increasing percentage of cases
of relatively lower risk and suggest that the shifts in incidence observed in the current study
are not attributable to changes in disease definition but rather epidemiologic changes in the
population.
There is substantial variability in the risk of progression to the lethal phenotype of muscle-
invasive (≥ T2) disease among the approximately 75% of patients initially presenting with
NMIBC. Patients with low-grade Ta tumors tend to have recurrent low-grade Ta tumors, at
rates of 30% to 70% by 5 years.5,18,19 In contrast, the 5-year risk of progression to ≥ T2
disease in these patients is ≤ 5%, with subgroups in the largest series showing rates of <
1%.5 In fact, the rates of recurrent, low-risk, noninvasive disease; progression to high-grade
NMIBC19; and invasive (≥ T2) cancer for patients with low-grade Ta bladder cancer are
similar to those reported in a pooled analysis of colorectal adenoma studies for recurrent
adenoma, progression to dysplastic polyp, and invasive (≥ T2) cancer, respectively.20 This is
in stark contrast to ≥ T2 progression rates of 30% to 70% in series of high-grade (T1 and/or
Tis disease) NMIBC.5,18 Given these dramatic differences in risk, the findings of the current
study in contemporary epidemiologic data suggesting a disproportionately increasing
fraction of elderly patients with low-risk pathology raise questions regarding not only the
etiology of this phenomenon but also the implications of these trends on cancer control
policy, given the burdens of survivorship care on patients and the health care system.3
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The observed clinical heterogeneity in this context motivated a body of molecular studies
implicating parallel, infrequently overlapping, biological pathways in the carcinogenesis of
the different phenotypes. As with many solid tumors, genomic instability and alterations in
cell cycle regulatory pathways are common among the poorer-risk sub-group,21,22 although
these are rare among patients with low-grade noninvasive disease.22 Activating mutations of
fibro-blast growth factor receptor 3 (FGFR3), similar to those found in congenital skeletal
dysplasias, have emerged as a prevalent (60%-95%) anomaly,22-24 rarely seen in other
tumor types.25 It is interesting to note that these mutations appear to be specific for
favorable-risk disease,22,26 reported to be mutually exclusive with p53 mutations detected in
94% of cases in 1 study.22 Building on these findings, several different FGFR3-based
“molecular grading” schemes have been investigated, which appear to offer superior
reproducibility and enhanced prognostic classification compared with standard
clinicopathological parameters.27
Given the relatively biphasic biology associated with different clinical phenotypes, our
observation of a specific increase in the incidence of lower-risk disease begs the question of
how differences in carcinogenesis might explain the observed trends. The classic risk factors
for bladder cancer are age, male sex, and environmental exposures, in particular cigarette
smoke28 and occupational exposures to aromatic amines.29 Data from population-based
case-control studies in the 1960s30 and 1970s31 suggested that early-stage and invasive
bladder cancer share most suspected risk factors. However, more recently, it was suggested
that smoking may be more strongly associated with the risk of invasive cancer than low-
grade superficial disease.32 It is interesting to note that smoking has also been specifically
associated with an increased risk of TP53 mutations but not activating mutations in
FGFR3.33 Several single-nucleotide polymorphisms have been associated with the specific
subphenotypes of low-grade and high-grade NMIBC and muscle-invasive disease.34 Further
research in more contemporary population-based cohorts is needed to assess the interaction
between different genotypes and exposure histories for the different clinical phenotypes.
Given our finding of a dramatically increasing incidence of noninvasive disease among the
oldest age strata, suggestive of a cohort effect (Fig. 3), age-period-cohort modeling
represents an attractive approach with which to explore the hypotheses generated in this
study.35 This approach has been used in this context to evaluate the contribution of temporal
changes in smoking as a driver of trends36; updating this work in contemporary data may be
particularly relevant given evidence of a recent increasing trend in smoking-related bladder
cancer risk, which suggests a potential period effect.37
The standard clinical management of patients with NMIBC includes transurethral resection
of the tumor followed by periodic surveillance cystoscopy; however, evidence informing
specific surveillance regimens is sparse, and practice guidelines are largely based on the
consensus of expert opinion.18 A consideration of the discordance between the
recommendations of relevant guidelines for the surveillance of patients newly diagnosed
with low-grade noninvasive bladder cancer highlights the uncertainty of management
decision-making. The European guidelines explicitly stratify patients based on risk and
recommend a specific, less aggressive surveillance schedule for patients with low-risk
disease.38 The American guidelines state that the most common approach includes patient
assessment performed every 3 months within the first 2 years after the initial diagnosis
followed by assessment every 6 months for the next 2 to 3 years and then annually
thereafter.2 Although the American guidelines do state that “a risk-adapted approach should
be considered,”2 no specific alternative schedule is outlined, leaving the relatively intensive
regimen as the default for all patients. Although this approach is certainly justifiable among
the subgroup of patients with high-risk (T1 and Tis) NMIBC, for which the surveillance
guidelines are concordant,2,38 our findings of high and increasing incidence rates for low-
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risk noninvasive papillary disease, predominantly among the oldest age strata, suggest that a
critical reevaluation of the essentially “1 size fits all” approach of the US clinical practice
guidelines may be warranted.
The strengths of the current study include the population-based sample, which facilitates the
calculation of adjusted incidence rates and supports the generalizability of these findings. In
addition, the restriction to those cases with urothelial histology supports our speculation
regarding risk group-specific carcinogenesis, as discussed above, as a potential explanatory
hypothesis. In sensitivity analyses, we found similar results with all bladder cancer cases,
with the exception of a parallel but higher incidence trend for ≥ T2 disease when including
nonurothelial subtypes, in which the percentage of ≥ T2 disease was 58% versus 21% in
urothelial-only subtypes (data not shown). These observational hypothesis-generating data
have limitations, including the possibility of misclassification or unmeasured changes in
stage reporting practices over time. We evaluated this in our sensitivity analyses and the
main result was still statistically significant. Nonetheless, the possibility of misclassification
remains, and future work with confirmatory centralized pathology review is needed. We
recognize that the stage crosswalk using SEER EOD/CS codes may misclassify some cases;
however, the consistency of our observed proportional changes over time with those
reported in another large independent data set using American Joint Committee on Cancer
TNM stage data6 are reassuring. Although to the best of our knowledge there has been no
systematic screening program or fundamental technological changes in the diagnosis of
bladder cancer over the study period,4 it is also possible that some as-yet unappreciated
secular changes in the diagnostic approach to hematuria in elderly patients may be
underway, given demographic changes and our observation of concomitant, albeit lower in
magnitude, decreases in the incidence of T1 and Tis cases. We adjusted for age, race, and
sex, which are well-recognized risk factors for overall diagnosis, stage at presentation, and
survival.6,39 Hispanic ethnicity has also been associated with a lower risk of bladder cancer,
although with similar stage distribution at diagnosis and survival, compared with non-
Hispanic Caucasians.39 SEER data regarding this variable are incomplete for the period of
interest, but we found that adding an adjustment for this variable among cases for which
there was available information did not significantly alter the findings (4.5% of cases had
Hispanic ethnicity; data not shown).
Conclusions
In this descriptive, hypothesis-generating study, we confirmed, using population-based data,
the suggestion from a prior hospital-based registry study of increases in the relative and
absolute incidence of noninvasive papillary (Ta) urothelial carcinoma of the bladder in
recent years. These findings support the need for further epidemiological study of potential
mechanisms, as well as scrutiny of the recommendations of clinical practice guidelines for
this large and growing population of predominantly elderly patients with lower-risk disease.
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Incidence rates for urothelial carcinoma of the bladder are shown adjusted for age, race, and
sex for overall, early-stage, and late-stage disease, 1988 to 2006.
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Stage-specific incidence rates for urothelial carcinoma of the bladder are shown adjusted for
age, race, and sex, 1988 to 2006, using Joinpoint regression analysis.
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Race- and sex-adjusted stage-specific incidence rates for urothelial carcinoma of the bladder
are shown by age strata, 1988 to 2006. Solid line with circles indicates Ta disease; solid line
with tick marks, Tis disease; dotted line, T1 disease; solid line, ≥ disease.
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Sensitivity analyses of incidence rates for urothelial carcinoma of the bladder adjusted for
age, race, and sex are shown, 1988 to 2006. (A, Top) Reclassification of low-grade Tis to Ta
using Joinpoint regression analysis is shown. (B, Bottom) Reclassification of Tx/unstaged to
Ta disease using Joinpoint regression analysis is shown.
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TABLE 1




EOD Extension,8 1st ed
1999-2003a
EOD Extension,10 3rd ed
2004-2006
CS Extension11
Ta 05 01, 03 010, 030
Tis 00, 10 06, 10 060, 100
T1 15, 30 15, 30 150, 155, 160, 165, 170, 300
≥T2 20-23, 40-85 20-23, 40-85 200-240, 400-810
Abbreviations: CS, collaborative staging; EOD: extent of disease; SEER, Surveillance, Epidemiology, and End Results.
a
Because the 3rd edition of the National Cancer Institute staging manual was released on January 1, 1998 and some registries had delays in
adoption, we allowed for cases to be coded under the 1st or 3rd edition.
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TABLE 3
Tests for Significant Changes in Adjusted Incidence Rates of Urothelial Carcinoma of the Bladder
Carriere and Roos Results14a Joinpoint Regression Resultsb
T Classification
Test Within Stage
1988 Versus 2006c P
Joinpoint
Location, Year APC1 (95% CI) APC2 (95% CI) AAPC (95% CI)
Ta 5.52 vs 9.09 <.0001 1991 11.2 (0.3-23.2)d 1.8 (1.3-2.3)d 3.3 (1.7-5.0)d
Tis 2.57 vs 1.19 <.0001 2003 −3.0 (−3.7 to −2.4)d −14.4 (−20.5 to −7.9)d −5.0 (−6.2 to −3.9)d
T1 6.65 vs 4.61 <.0001 1997 −4.6 (−5.9 to −3.2)d 1.6 (0.5-2.6)d −1.6 (−2.4 to −0.8)d
≥T2 3.87 vs 3.86 .9491 – 0.1 (−0.2 to 0.3) – 0.1 (−0.2 to 0.3)
Tx/unstaged 0.73 vs 0.37 <.0001 – −5.1 (−6.0 to −4.3)d −5.1 (−6.0 to −4.3)d
Abbreviations: 95% CI, 95% confidence interval; AAPC, average annual percentage change; APC, annual percentage change.
a
Within-stage comparisons over the study period.
b
APC and AAPC shown by T classification (adjusted for age, race, and sex).
c
Within-stage comparisons over the study period reflect incidence rates adjusted for age, race, and sex (per 100,000) at the first (1988) and last
(2006) years of the study period.
d
The APC/AAPC was significantly different from 0 at an α of .05.
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TABLE 4
Sensitivity Analyses For Significant Changes in Adjusted Incidence Rates: Within-Stage Comparisons Over
the Study Period, APC and AAPC by T Classification Adjusted for Age, Race, and Sex









Location, Year APC1 (95% CI) APC2 (95% CI) APC3 (95% CI) AAPC (95% CI)
Reclassifying Tareclassified 7.31 vs 9.55 <.0001 1991, 2004 +7.4 (1.3-13.9)b +1.0 (0.6-1.4)b −2.7 (−7.8 to
2.7)
+1.6 (0.5-2.7)b




 Tis to Ta
Ta 5.52 vs 9.09 <.0001 1991 +11.2 (0.3-23.2)b +1.8 (1.3-2.3)b +3.3 (1.7-5.0)b














6.25 vs 9.46 <.0001 1991 +9.7 (0.1-20.2)b +1.3 (0.9-1.8)b +2.7 (1.2-4.2)b
Abbreviations: 95% CI, 95% confidence interval; AAPC, average annual percentage change; APC, annual percentage change.
a
Within-Stage comparisons over the study period reflect incidence rates adjusted by age, race, and sex (per 100,000) at the first (1988) and last
(2006) years of the study period.
b
The APC/AAPC was significantly different from 0 at an α of .05.
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